## DGX: Quest Diagnostics Incorporated - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.46 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-1.7% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($169.52)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Aaron Wealth Advisors LLC Makes New Investment in Quest Diagnostics Incorporated $DGX**
- Source: MarketBeat | 20251217T082317 | Somewhat-Bullish | Relevance: 97%
- Aaron Wealth Advisors LLC has initiated a new investment in Quest Diagnostics (DGX), acquiring 7,618 shares valued at approximately $1.45 million. This comes as institutional investors now hold about 88.06% of the stock, despite recent significant insider selling, including the CEO reducing his stake by over 31%. Quest Diagnostics reported strong Q3 earnings, exceeding analyst estimates, and announced a quarterly dividend, with analysts maintaining a "Moderate Buy" consensus rating for the company.

**2. Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector?**
- Source: Barchart.com | 20251216T124258 | Somewhat-Bullish | Relevance: 70%
- Bio-Techne Corporation (TECH), a mid-cap life sciences company, has underperformed the Health Care Select Sector SPDR Fund (XLV) year-to-date and over the past 52 weeks, despite a recent three-month gain. The company's Q1 2026 revenue declined due to headwinds in cell therapy timing and biotech funding softness. Despite its recent struggles, analysts maintain a "Strong Buy" rating for TECH with a significant upside to its mean price target.

**3. Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector?**
- Source: Markets Financial Content | 20251216T074000 | Somewhat-Bullish | Relevance: 63%
- Bio-Techne Corporation (TECH) has shown underperformance compared to the broader healthcare sector (XLV), with its stock decreasing almost 26% from its 52-week high. While it gained 13.7% in the past three months, it lagged XLV's 14% gain. The company's recent Q1 2026 revenue decline due to cell therapy timing and biotech funding softness contributed to investor concerns, despite analysts maintaining a "Strong Buy" rating.

**4. Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector?**
- Source: Palmetto Grain Brokerage | 20251216T120846 | Somewhat-Bullish | Relevance: 60%
- Bio-Techne Corporation (TECH) has seen its shares decrease by nearly 26% from its 52-week high, lagging behind the Health Care Select Sector SPDR Fund (XLV) over the past three months and year-to-date. The company reported a 1% year-over-year revenue decline in Q1 2026, pressured by cell therapy timing headwinds and biotech funding softness. Despite its underperformance compared to rivals like Quest Diagnostics Incorporated (DGX), analysts maintain a "Strong Buy" rating with a significant price target premium.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 9 ($1.18M) |
| Sells | 8 ($8.86M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.8% (+0.1%)
- Blackrock Inc.: 9.0% (-3.0%)
- JPMORGAN CHASE & CO: 7.8% (+99.3%)
- Price (T.Rowe) Assoc: 6.3% (-2.6%)
- State Street Corpora: 4.7% (+0.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-1.7% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $8.9M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.46 suggests fair value with growth premium. Forward P/E 17.0x stretched relative to 6% growth. Insider selling cluster ($8.9M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.7B |
| Beta | 0.62 |
| 52W Range | $148.70 - $197.55 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.46 |
| Forward P/E | 17.0 |
| Current P/E | 18.0 |
| YoY Growth | 5.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -1.9% to -3.6% (-1.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.6pp (needs >4.0% for momentum thesis). AM_20 at -4.2% indicates price below own 20MA trend. Underperforming sector by 4.0pp, stock-specific weakness. Below SMA200 (0.99x), long-term trend not supportive. MACD histogram bearish (-0.81), momentum weakening. OFD pattern: -FTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.60% (CS: 14) | Weak |
| RSI_14 | 36.8 | Neutral |
| MACD Histogram | -0.81 | Bearish |
| vs SMA20 | 0.958x | Below |
| vs SMA50 | 0.961x | Below |
| vs SMA200 | 0.995x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $176.16
- **Stop Loss:** $169.52 (3.8% risk)
- **Target:** $189.44 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 143
- **Position Value:** $25,190.88
- **Portfolio %:** 25.19%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-01-27 (Est: $2.36)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.60 | +3.9% |
| 2025Q2 | $2.57 | $2.62 | +1.9% |
| 2025Q1 | $2.15 | $2.21 | +2.8% |
| 2024Q4 | $2.18 | $2.23 | +2.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*